Common questions about Afinitor (FAQ)
Q: What is the main difference between Afinitor and other targeted therapy drugs?
A: Afinitor (everolimus) is officially described as a selective inhibitor of mTORC1 (mechanistic Target of Rapamycin Complex 1). This mechanism focuses on blocking a specific cellular pathway that controls cell growth and division, which is a key way it differs from other classes of targeted therapies.
Q: Can Afinitor cause issues with blood cell counts?
A: Yes. According to the official product information, anemia (a low red blood cell count) is a very common adverse reaction. Low counts of white blood cells (leukopenia) and platelets have also been reported. Regulatory documents indicate that monitoring of complete blood counts is required prior to and periodically throughout treatment.
Q: Does Afinitor cause hair loss?
A: Hair loss (alopecia) is not typically listed as one of the most common side effects when Afinitor is used alone. However, official labeling notes that alopecia has been commonly reported when this medicine is used in combination with exemestane for advanced breast cancer.
Q: Can Afinitor affect kidney function over time?
A: Official information indicates that kidney failure has been reported in patients taking Afinitor. For this reason, the prescribing information requires monitoring of renal (kidney) function prior to and periodically throughout treatment.
Q: Does Afinitor interact with any specific foods or beverages?
A: Yes, regulatory documents state that the consumption of grapefruit, grapefruit juice, and certain other fruits like star fruit or Seville oranges should be avoided while on treatment. These items can significantly affect the amount of medicine absorbed into the bloodstream.
Q: What is the experience with Afinitor use in pediatric populations for specific conditions?
A: Afinitor Disperz is approved for specific conditions associated with Tuberous Sclerosis Complex (TSC) in children, such as SEGA and partial-onset seizures. Studies focusing on these specific indications have reported a reduction in tumor or lesion volume in a significant proportion of patients.
Q: Can Afinitor affect a person's ability to have children in the future?
A: Regulatory documents indicate that Afinitor (everolimus) has been shown in animal studies to potentially affect male and female fertility. Concerns regarding future childbearing are best discussed with a healthcare provider.
Q: Does Afinitor treatment have any known effects on wound healing?
A: Afinitor is associated with impaired wound healing. Regulatory documents state that caution is advised when using the medicine in patients with recent surgery or unhealed wounds, as it might affect the speed and quality of healing.
Q: Can Afinitor cause or reactivate a prior Hepatitis B infection?
A: The use of Afinitor may lead to the reactivation of Hepatitis B virus (HBV) in individuals who have previously had the infection. Regulatory documents indicate that monitoring and appropriate treatment are required if HBV reactivation occurs.
Q: Do Afinitor side effects depend on the condition being treated, such as kidney cancer versus breast cancer?
A: While many of the most frequent side effects (such as stomatitis, rash, and fatigue) are consistently reported across all approved indications, the frequency and severity of some adverse events can vary slightly depending on the specific patient population and condition being treated.
Q: Is it possible for Afinitor to be taken alongside other targeted or hormone therapies?
A: Yes. For example, Afinitor is used in combination with the hormone therapy exemestane for advanced breast cancer, as supported by clinical trial data. The decision to use it with any other targeted therapy is based on specific regulatory approval for the combination.
Q: What is the risk of getting infections while taking Afinitor?
A: Afinitor is associated with an increased risk of serious and potentially fatal infections. The official safety information states that patients should be vigilant for signs of infection. Additionally, pre-existing infections are generally advised to be fully resolved before the medicine is started.
Q: What is the general duration of treatment with Afinitor?
A: Regulatory documents state that treatment should be continued for as long as a patient is benefiting from the medicine. This means treatment lasts until the disease progresses (gets worse) or until unacceptable toxicity (side effects) occurs.
Q: Can the side effects of Afinitor lessen or change over a long period of treatment?
A: Official data indicates that many side effects, particularly stomatitis (mouth sores), are more commonly reported during the initial 8 weeks of treatment. Ongoing safety monitoring allows for management of side effects that are persistent or change over time.
Q: Are there any known restrictions for patients with pre-existing heart conditions?
A: While specific pre-existing heart conditions are not listed as an absolute restriction, regulatory documents have reported severe cardiac adverse reactions as uncommon side effects, including congestive heart failure. Concerns regarding heart conditions are best addressed by a healthcare provider.
Q: Can Afinitor cause peripheral edema (swelling of the ankles or feet)?
A: Yes, official regulatory documents list edema as a very common adverse reaction. Edema is defined as swelling of the hands, ankles, feet, or other parts of the body.
Q: Is it possible to have high blood pressure while on Afinitor therapy?
A: Yes, hypertension (high blood pressure) is listed as a common adverse reaction in the regulatory product information. Blood pressure monitoring is typically conducted as part of the overall treatment plan.
Q: Why does Afinitor sometimes require taking an additional mouthwash?
A: Because stomatitis (mouth sores or ulcers) is the most frequently reported side effect, some regulatory information notes the use of an alcohol-free corticosteroid oral solution (mouthwash). This solution has been studied to potentially decrease the incidence and severity of mouth sores when used during the initial period of treatment.
Q: What is the typical timeframe before the effects of Afinitor are observed?
A: Studies related to the mechanism of action show that the medicine reaches steady-state concentrations in the body within approximately two weeks of starting once-daily dosing. The clinical effects on disease progression are generally assessed over a longer period in clinical trials.
Q: Does Afinitor have any known neurological side effects like headache or dizziness?
A: Regulatory documents list headache as a very common adverse reaction. While dizziness is not listed as common, it has been reported as a symptom related to other side effects, such as anemia.
Q: Can Afinitor affect a person's sense of taste?
A: Yes, dysgeusia (a change in the sense of taste) is listed as a very common adverse reaction in the regulatory product information.
Q: Does the brand name Afinitor have a generic version available?
A: Yes, the FDA has approved generic versions of the active ingredient, everolimus, in various tablet strengths for the approved indications. The decision regarding the use of brand or generic versions is made in consultation with a healthcare provider.
Q: How often are blood tests or lab work typically required while on Afinitor?
A: Monitoring of blood counts, blood glucose, and liver/kidney function is required prior to treatment and periodically throughout the treatment course. For certain specific uses, such as in Tuberous Sclerosis Complex, blood concentrations are assessed approximately 1 to 2 weeks after starting or changing the dose.
